IP Library Granted Patent US 12,488,901
Granted Patent B2
US 12,488,901 · App. 19/178,472 · Granted Dec 2, 2025

Personalized wellness systems and methods of use

Inventors: James Crouch (Boulder, CO); Sean Callan (Denver, CO)
G16H50/30G16B20/00G16B40/00G16H10/40G16H10/60G16H20/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,488,901
App. No.
19/178,472
Granted
Dec 2, 2025
Kind
B2
Abstract

A health and wellness system for a non-human subject comprising analyzing genetic data and phenotypic data of the non-human subject with a machine learning algorithm and making a recommendation or recommendation for products or activities for the non-human subject.

Claims (30)

1 . A method of producing a personalized combination nutritional product, the method comprising assembling a combination product comprising a food and a nutritional supplement for a non-human animal subject based, at least in part on:

(a) receiving:

genetic data at a plurality of genomic loci of the non-human animal subject, wherein at least one genomic locus of the plurality of genomic loci is associated with a first condition, wherein the first condition is not a breed type;

phenotypic data pertaining to a plurality of phenotypes of the non-human animal subject that is associated with a second condition, wherein the plurality of phenotypes comprises a species, a food allergy, an age, a weight, or a breed; and

environmental data for the non-human animal subject that is associated with a third condition, wherein the environmental data comprises a climate or geographical location of residence;

(b) processing a data set comprising the genetic data, the phenotypic data, and the environmental data to determine qualitative or quantitative measures of each that predict whether the non-human animal subject is likely to have or develop the first condition, the second condition, and the third condition; and

(c) ranking at least two of the first condition, the second condition, and the third condition to identify a highest-ranking condition for the non-human animal subject, wherein the combination product improves, ameliorates, or prevents the highest-ranking condition.

2 . The method of claim 1 , wherein the food comprises a kibble, a wet food, a canned food, a fresh food, or any combination thereof.

3 . The method of claim 1 , where the combination product further comprises a medication.

4 . The method of claim 1 , wherein the combination product further comprises a treat.

5 . The method of claim 1 , wherein the nutritional supplement comprises a probiotic.

6 . The method of claim 1 , wherein the food comprises one or more additives relative to a standard food as determined by Association of American Feed Control Officials (AAFCO) guidelines or guidelines of a similar standard-setting body corresponding to the non-human animal subject, wherein the one or more additives, at least in part, improves, ameliorates, or prevents the highest-ranking condition.

7 . The method of claim 1 , wherein the food comprises an increased or a decreased amount of an existing ingredient of a standard food as determined AAFCO guidelines or guidelines of a similar standard-setting body corresponding to the non-human animal subject, wherein the increased or the decreased amount of the existing ingredient, at least in part, improves, ameliorates, or prevents the highest-ranking condition.

8 . The method of claim 1 , wherein the combination product is complete and balanced as determined by AAFCO or a similar standard-setting body corresponding to the non-human animal subject.

9 . The method of claim 1 , wherein the non-human animal subject is a mixed-breed animal.

10 . The method of claim 1 , wherein the improvement, amelioration, or prevention of the highest-ranking condition is associated with an increase in one or more ingredients in the combination product, wherein the increase is relative to a current diet of the non-human animal subject.

11 . The method of claim 1 , wherein improvement, amelioration, or prevention of the highest-ranking condition is associated with a decrease in one or more ingredients in the combination product, wherein the decrease is relative to a current diet of the non-human animal subject.

12 . The method of claim 1 , wherein the highest-ranking condition is associated with a deficiency in, or excess of, a vitamin, a mineral, or an antioxidant.

13 . The method of claim 1 , wherein the highest-ranking condition is a disease.

14 . The method of claim 13 , wherein the disease affects liver function or kidney function.

15 . The method of claim 1 , wherein the ranking is performed based, at least in part, on

(i) the severity of the at least two of the first condition, the second condition, and the third condition;

(ii) an impact to quality of life of the non-human animal subject living with the first condition, the second condition, or the third condition;

(iii) an estimated life span of the non-human animal subject living with the first condition, the second condition, or the third condition; or

(iv) any combination of (i)-(iii).

16 . The method of claim 1 , wherein the food is formulated to improve, ameliorate, or prevent the highest-ranking condition and one or more additional conditions identified based, at least in part, on the data set.

17 . The method of claim 1 , wherein the food improves, ameliorates, or prevents the highest-ranking condition and the nutritional supplement improves, ameliorates, or prevents a second highest-ranking condition of the first condition, the second condition, and the third condition.

18 . The method of claim 1 , further comprising receiving activity data for the non-human animal subject that comprises an activity level, an activity type, calories burned, or time asleep for the non-human animal subject, wherein the data set further comprises the activity data.

19 . The method of claim 1 , further comprising receiving behavioral data for the non-human animal subject that comprises chewing, itching, aggression, neurosis, anxiety, or energy level of the non-human animal subject, wherein the data set further comprises the behavioral data.

20 . The method of claim 1 , wherein the non-human animal subject is a companion animal.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2025
From: CROUCH, JAMES; CALLAN, SEAN
To: ONIKOROSHI, LLC
Reel/Frame 070908/0614 →
Continuity (3)
Continuation 18353737 · Jul 17, 2023
Provisional Application 63513589 · Jul 14, 2023
Related Publication 20250246315A1 · Jul 31, 2025
References Cited (131)
US 6287254B1 · Dodds · 2001 [cited by applicant]
US 6358546B1 · Bebiak et al. · 2002 [cited by applicant]
US 6493641B1 · Singh et al. · 2002 [cited by applicant]
US 6537213B2 · Dodds · 2003 [cited by applicant]
US 6730023B1 · Dodds · 2004 [cited by applicant]
US 7029441B2 · Dodds · 2006 [cited by applicant]
US 7134995B2 · Dodds · 2006 [cited by applicant]
US 7548839B2 · Dodds · 2009 [cited by applicant]
US 7552039B2 · Dodds · 2009 [cited by applicant]
US 7797145B2 · Dodds · 2010 [cited by applicant]
US 7865343B2 · Dodds · 2011 [cited by applicant]
US 7873482B2 · Stefanon et al. · 2011 [cited by applicant]
US 7970552B1 · Stefanon et al. · 2011 [cited by applicant]
US 8060354B2 · Dodds · 2011 [cited by applicant]
US 8234099B2 · Dodds · 2012 [cited by applicant]
US 9242765B2 · Oziomek et al. · 2016 [cited by applicant]
US 9420809B2 · Donavon et al. · 2016 [cited by applicant]
US 10468141B1 · Valenzuela et al. · 2019 [cited by applicant]
US 11482340B1 · Kenedy et al. · 2022 [cited by applicant]
US 11495360B2 · Kenedy et al. · 2022 [cited by applicant]
US 11501851B2 · Sams et al. · 2022 [cited by applicant]
US 12322515B2 · Crouch et al. · 2025 [cited by applicant]
US 20020022772A1 · Dodds · 2002 [cited by applicant]
US 20030004655A1 · Singh et al. · 2003 [cited by applicant]
US 20040131658A1 · Kaput · 2004 [cited by applicant]
US 20050065736A1 · Bauck et al. · 2005 [cited by applicant]
US 20050090718A1 · Dodds · 2005 [cited by applicant]
US 20050158734A1 · Kaput · 2005 [cited by applicant]
US 20060045909A1 · Friesen · 2006 [cited by examiner]
US 20060200320A1 · Al-Murrani · 2006 [cited by applicant]
US 20060235625A1 · Ostrander et al. · 2006 [cited by applicant]
US 20070110789A1 · Pan · 2007 [cited by examiner]
US 20070118295A1 · Al-Murrani · 2007 [cited by applicant]
US 20100304396A1 · Dodds · 2010 [cited by applicant]
US 20110153221A1 · Stefanon et al. · 2011 [cited by applicant]
US 20110246405A1 · Dodds · 2011 [cited by applicant]
US 20120185175A1 · Dodds · 2012 [cited by applicant]
US 20120303286A1 · Dodds · 2012 [cited by applicant]
US 20120309639A1 · Hakonarson et al. · 2012 [cited by applicant]
US 20140141131A1 · Oziomek et al. · 2014 [cited by applicant]
US 20140141134A1 · Johnson et al. · 2014 [cited by applicant]
US 20140257047A1 · Sillay et al. · 2014 [cited by applicant]
US 20140272028A1 · Donavon et al. · 2014 [cited by applicant]
US 20150072048A1 · Potthoff et al. · 2015 [cited by applicant]
US 20150242566A1 · Samer · 2015 [cited by applicant]
US 20150286774A1 · Lohi et al. · 2015 [cited by applicant]
US 20160364522A1 · Frey et al. · 2016 [cited by applicant]
US 20170220734A1 · Colavin et al. · 2017 [cited by applicant]
US 20180328945A1 · Nova et al. · 2018 [cited by applicant]
US 20190295691A1 · Garshon et al. · 2019 [cited by applicant]
US 20190392927A1 · Ku · 2019 [cited by applicant]
US 20210287758A1 · Wong et al. · 2021 [cited by applicant]
US 20230061512A1 · Sams et al. · 2023 [cited by applicant]
US 20230106107A1 · Boyko et al. · 2023 [cited by applicant]
US 20230157320A1 · Roche et al. · 2023 [cited by applicant]
US 20230335258A1 · Sinha et al. · 2023 [cited by applicant]
US 20240185988A1 · Carson et al. · 2024 [cited by applicant]
US 20250022602A1 · Crouch et al. · 2025 [cited by applicant]
US 20250046463A1 · Bennett et al. · 2025 [cited by applicant]
US 20250087374A1 · Kenedy et al. · 2025 [cited by applicant]
EP 4062411A1 · 2022 [cited by applicant]
EP 4127224A1 · 2023 [cited by applicant]
IN 202541031075 · 2025 [cited by applicant]
WO WO2007049157A2 · 2007 [cited by applicant]
WO WO2008103827A1 · 2008 [cited by applicant]
WO WO2012129507A1 · 2012 [cited by applicant]
WO WO2016005911A1 · 2016 [cited by applicant]
WO WO2019143714A1 · 2019 [cited by applicant]
WO WO2020109858A1 · 2020 [cited by applicant]
WO WO2021101896A1 · 2021 [cited by applicant]
WO WO2021202910A1 · 2021 [cited by applicant]
WO WO2021207370A1 · 2021 [cited by applicant]
WO WO2025019285A2 · 2025 [cited by applicant]
AAFCO, PFC Committee Report/Minutes AAFCO Annual Meeting Aug. 4, 2015; Denver, CO. (2015). Available at https://www.aafco.org/wp-content/uploads/2023/01/Pet_Food_Report_2015_Annual.pdf. [cited by applicant]
Ahner et al., Protein biomarkers in serum and urine for determining presence or absence of hip dysplasia in a canine model. J Orthop Res. 37(4):916-920 (2019). [cited by applicant]
Almela et al., Selected serum oxidative stress biomarkers in dogs with non-food-induced and food-induced atopic dermatitis. Vet Dermatol. 29(3):229-e82 (2018). [cited by applicant]
Asahina et al., Serum canine thymus and activation-regulated chemokine (TARC/CCL17) concentrations correlate with disease severity and therapeutic responses in dogs with atopic dermatitis. Vet Dermatol. 31(6):446-455 (2… [cited by applicant]
Axelsson et al., The genomic signature of dog domestication reveals adaptation to a starch-rich diet. Nature. 495(7441):360-364 (2013). [cited by applicant]
Basepaws Veterinary, Basepaws canine baseline genetic tests. Basepaws Veterinary by Zoetis. (2022). Available at https://basepawsvet.com/canine-products. [cited by applicant]
Basepaws Veterinary, Basepaws feline genetic & oral microbiome tests. Basepaws Veterinary by Zoetis. (2022). Available at https://basepawsvet.com/feline-products. [cited by applicant]
Bergström et al., Origins and genetic legacy of prehistoric dogs. Science. 370(6516):557-564 (2020). [cited by applicant]
Biber Ingenity: 877-Igenity. Bieber Red Angus Ranch. (2018). Available at https://bieberredangus.com/igenity/. [cited by applicant]
Cardona-Ramírez et al., The differentiating ability of four plasma biomarkers in canine hip dysplasia. Vet Clin Pathol. 48(2):320-327 (2019). [cited by applicant]
Carlos et al., Canine metabolomics advances. Metabolomics. 16(2):16 (2020). [cited by applicant]
Chon et al., Genomic tumor analysis provides clinical guidance for the management of diagnostically challenging cancers in dogs. J Am Vet Med Assoc. 261(5):668-677 (2023). [cited by applicant]
Co-pending U.S. Appl. No. 18/858,819, inventors Cameron; Gordon Craig et al., filed Oct. 22, 2024. [cited by applicant]
Donner et al., Genetic prevalence and clinical relevance of canine Mendelian disease variants in over one million dogs. PLoS Genet. 19(2):e1010651 (2023). [cited by applicant]
Embark, Better care for your patients is in their DNA. (2022). Available at https://embarkvet.com/vets/. [cited by applicant]
Forcada et al., A genome-wide association study identifies novel candidate genes for susceptibility to diabetes mellitus in non-obese cats. PLoS One. 16(12):e0259939 (2021). [cited by applicant]
Gjuvsland, Arne B. et al. Bridging the Genotype-phenotype Gap: What Does It Take ?. The Journal of Physiology 591(8):2055-2066 (2013). [cited by applicant]
González-Arostegui et al., Changes in biomarkers of redox status in serum and saliva of dogs with hypothyroidism. BMC Vet Res. 9(1):33 (2023). [cited by applicant]
González-Arostegui et al., Changes in the salivary metabolome in canine hypothyroidism: A pilot study. Res Vet Sci. 151:189-195 (2022). [cited by applicant]
Heishima et al., Circulating microRNA-214 and—126 as potential biomarkers for canine neoplastic disease. Sci Rep. 7(1):2301 (2017). [cited by applicant]
Hokamp et al., Renal biomarkers in domestic species. Vet Clin Pathol. 45(1):28-56 (2016). [cited by applicant]
IAMS, IAMS™ Pet Food + Wisdom Panel™ DNA test for Cats & Dogs (2023). Available at https://www.iams.com/wisdom-panel. [cited by applicant]
Jones, Best dog DNA tests 2023: DNA My Dog vs Wisdom Panel vs Embark vs Orivet vs EasyDNA & More. Canine Journal. May 23, 2023. [cited by applicant]
Koury et al., Phosphodiesterase 4D, miR-203 and selected cytokines in the peripheral blood are associated with canine atopic dermatitis. PLoS One. 14(6):e0218670 (2019). [cited by applicant]
Lindblad-Toh et al., Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature. 438(7069):803-819 (2005). [cited by applicant]
Marsella, Advances in our understanding of canine atopic dermatitis. Vet Dermatol. 32(6):547-e151 (2021). [cited by applicant]
Martins et al., Clinical-pathological and immunological biomarkers in dogs with atopic dermatitis. Vet Immunol Immunopathol. 205:58-64 (2018). [cited by applicant]
Mazaki-Tovi et al., Increased serum leptin and insulin concentrations in canine hypothyroidism. Vet J. 183(1):109-114 (2010). [cited by applicant]
Mcconnel, Blair. For the Future of Pet Care Genomics, Look to Livestock. Linkedin. Available at https://www.linkedin.com/pulse/future-pet-care-genomics-look-livestock-blair-mcconnel-dukce/?trackingId=VAHXLpRfYpw327ytZEd… [cited by applicant]
Meddens et al., Genomic analysis of diet composition finds novel loci and associations with health and lifestyle. Mol Psychiatry. 26(6):2056-2069 (2021). [cited by applicant]
Muñoz-Prieto et al., Untargeted metabolomic profiling of serum in dogs with hypothyroidism. Res Vet Sci. 136:6-10 (2021). [cited by applicant]
Neogen, Igenity® Beef: Item No. 44—Brochure and Technical Specification sheet. (2023). Available at https://www.neogen.com/categories/igenity-profiles/igenity-beef/?min=GS_SL_44. [cited by applicant]
Neogen, Igenity® Canine Wellness. (2020). Available at https://www.neogen.com/igenity-canine-wellness/. [cited by applicant]
O'Kell et a., Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes. Sci Rep. 7(1):9467 (2017). [cited by applicant]
O'Kell et al., Untargeted metabolomic analysis in non-fasted diabetic dogs by UHPLC-HRMS. Metabolomics. 15(2):15 (2019). [cited by applicant]
Pallotti et al., Dog-human translational genomics: state of the art and genomic resources. J Appl Genet. 63(4):703-716 (2022). [cited by applicant]
PCT/US2024/037714 International Search Report and Written Opinion dated Dec. 11, 2024. [cited by applicant]
PCT/US2024/037714 Invitation to pay additional fees dated Sep. 11, 2024. [cited by applicant]
Pet Business, IAMS, Wisdom Panel Partner on Genetics-Based Nutrition. Pet Business digitalmag, 2pgs. May 2023. Available at https://digitalmag.petbusiness.com/petbusiness/library/item/may_2023/4102425/. [cited by applicant]
Piras et al., Identification of genetic susceptibility factors associated with canine gastric dilatation-volvulus. Genes (Basel). 11(11):1313 (2020). [cited by applicant]
Plassais et al., Analysis of large versus small dogs reveals three genes on the canine X chromosome associated with body weight, muscling and back fat thickness. PLoS Genet. 13(3):e1006661 (2017). [cited by applicant]
Royal Canin, Discover the secrets of your dog's DNA—Genetic Health Analysis. (2023) Available at https://www.royalcanin.com/us/dogs/genetic-health-analysis. [cited by applicant]
Ryad et al., Oxidative biomarkers and lipid alterations in euthyroid and hypothyroid dogs. Comp Clin Pathol. 30:571-576 (2021). [cited by applicant]
Santoro et al., Evaluation of cutaneous and circulating (serum and exosomes) levels of chemokines (CCL17, CCL22, CCL27 and CCL28) in atopic dogs and their correlation with severity of the disease. Vet Dermatol. 33(3):19… [cited by applicant]
U.S. Appl. No. 18/353,737 Notice of Allowance dated Apr. 1, 2025. [cited by applicant]
U.S. Appl. No. 18/353,737 Office Action dated Feb. 13, 2025. [cited by applicant]
U.S. Appl. No. 18/353,737 Office Action dated Jan. 18, 2024. [cited by applicant]
U.S. Appl. No. 18/353,737 Office Action dated Jul. 31, 2024. [cited by applicant]
U.S. Appl. No. 18/353,737 Office Action dated Jun. 7, 2024. [cited by applicant]
U.S. Appl. No. 18/353,737 Office Action dated Nov. 27, 2024. [cited by applicant]
Vidium, SearchLight DNA™ for veterinarians. (2023). Available at https://vidiumah.com/searchlight-dna/. [cited by applicant]
Wang et al.; Genome-wide association studies for canine hip dysplasia in single and multiple populations—implications and potential novel risk loci. BMC Genomics. 22(1):636 (2021). [cited by applicant]
Williams et al., Body Condition Scores. VCA Animal Hospital. (2023). Available at https://vcahospitals.com/know-your-pet/body-condition-scores. [cited by applicant]
Winiarczyk et al., Proteomic analysis of tear film obtained from diabetic dogs. Animals. 10(12):2416 (2020). [cited by applicant]
Wood et al., Genome-wide association analysis of canine atopic dermatitis and identification of disease related SNPs. Immunogenetics. 61(11-12):765-772 (2009). [cited by applicant]
Zelezniak et al., Machine learning predicts the yeast metabolome from the quantitative proteome of kinase knockouts. Cell Syst. 7(3): 269-283.e6 (2018). [cited by applicant]
Petdx, Early Cancer Detection in Dogs with a Simple Blood Draw. 22 pages (2023). Available at https://web.archive.org/web/20230701214733/https://petdx.com/. [cited by applicant]
Wisdompanel, Royal Canin® Genetic Health Analysis™ : disease and mutation tests. 144 pages. (2023). Available at https://web.archive.org/web/20230922093451/https://wisdompanel.my.salesforce-sites.com/royalcaningha/. [cited by applicant]